These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
184 related articles for article (PubMed ID: 30899597)
1. A selective inhibitor of the Polo-box domain of Polo-like kinase 1 identified by virtual screening. Abdelfatah S; Berg A; Böckers M; Efferth T J Adv Res; 2019 Mar; 16():145-156. PubMed ID: 30899597 [TBL] [Abstract][Full Text] [Related]
2. MCC1019, a selective inhibitor of the Polo-box domain of Polo-like kinase 1 as novel, potent anticancer candidate. Abdelfatah S; Berg A; Huang Q; Yang LJ; Hamdoun S; Klinger A; Greten HJ; Fleischer E; Berg T; Wong VKW; Efferth T Acta Pharm Sin B; 2019 Sep; 9(5):1021-1034. PubMed ID: 31649851 [TBL] [Abstract][Full Text] [Related]
3. Identification of inhibitors of the polo-box domain of polo-like kinase 1 from natural and semisynthetic compounds. Abdelfatah S; Fleischer E; Klinger A; Wong VKW; Efferth T Invest New Drugs; 2020 Feb; 38(1):1-9. PubMed ID: 30877426 [TBL] [Abstract][Full Text] [Related]
4. [Mining Polo-Box domain of Polo-like kinase 1 as a new therapeutic target for cancer]. Fu Z; Su M; Liu X; Chen Y Sheng Wu Gong Cheng Xue Bao; 2020 Nov; 36(11):2298-2312. PubMed ID: 33244925 [TBL] [Abstract][Full Text] [Related]
5. Identification of a novel Polo-like kinase 1 inhibitor that specifically blocks the functions of Polo-Box domain. Chen Y; Zhang J; Li D; Jiang J; Wang Y; Si S Oncotarget; 2017 Jan; 8(1):1234-1246. PubMed ID: 27902479 [TBL] [Abstract][Full Text] [Related]
6. Identification of naphthalimide-derivatives as novel PBD-targeted polo-like kinase 1 inhibitors with efficacy in drug-resistant lung cancer cells. Li P; Li Y; Ma X; Li L; Zeng S; Peng Y; Liang H; Zhang G Eur J Med Chem; 2024 May; 271():116416. PubMed ID: 38657480 [TBL] [Abstract][Full Text] [Related]
7. Selective blockade of cancer cell proliferation and anchorage-independent growth by Plk1 activity-dependent suicidal inhibition of its polo-box domain. Park JE; Kim TS; Kim BY; Lee KS Cell Cycle; 2015; 14(22):3624-34. PubMed ID: 26513691 [TBL] [Abstract][Full Text] [Related]
8. Structure-Based Virtual Screening and Biological Evaluation of Peptide Inhibitors for Polo-Box Domain. Yan F; Liu G; Chen T; Fu X; Niu MM Molecules; 2019 Dec; 25(1):. PubMed ID: 31892137 [TBL] [Abstract][Full Text] [Related]
9. The natural product Aristolactam AIIIa as a new ligand targeting the polo-box domain of polo-like kinase 1 potently inhibits cancer cell proliferation. Li L; Wang X; Chen J; Ding H; Zhang Y; Hu TC; Hu LH; Jiang HL; Shen X Acta Pharmacol Sin; 2009 Oct; 30(10):1443-53. PubMed ID: 19801998 [TBL] [Abstract][Full Text] [Related]
10. Discovery of Novel Polo-Like Kinase 1 Polo-Box Domain Inhibitors to Induce Mitotic Arrest in Tumor Cells. Qin T; Chen F; Zhuo X; Guo X; Yun T; Liu Y; Zhang C; Lai L J Med Chem; 2016 Aug; 59(15):7089-96. PubMed ID: 27425654 [TBL] [Abstract][Full Text] [Related]
11. Cell type-- dependent effects of Polo-like kinase 1 inhibition compared with targeted polo box interference in cancer cell lines. Fink J; Sanders K; Rippl A; Finkernagel S; Beckers TL; Schmidt M Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3189-97. PubMed ID: 18089713 [TBL] [Abstract][Full Text] [Related]
12. Design and synthesis of a cell-permeable, drug-like small molecule inhibitor targeting the polo-box domain of polo-like kinase 1. Srinivasrao G; Park JE; Kim S; Ahn M; Cheong C; Nam KY; Gunasekaran P; Hwang E; Kim NH; Shin SY; Lee KS; Ryu E; Bang JK PLoS One; 2014; 9(9):e107432. PubMed ID: 25211362 [TBL] [Abstract][Full Text] [Related]
13. Identification of green tea catechins as potent inhibitors of the polo-box domain of polo-like kinase 1. Shan HM; Shi Y; Quan J ChemMedChem; 2015 Jan; 10(1):158-63. PubMed ID: 25196850 [TBL] [Abstract][Full Text] [Related]
14. Differential Cellular Effects of Plk1 Inhibitors Targeting the ATP-binding Domain or Polo-box Domain. Shin SB; Woo SU; Yim H J Cell Physiol; 2015 Dec; 230(12):3057-67. PubMed ID: 25975351 [TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and evaluation of d-amino acid-containing peptidomimetics targeting the polo-box domain of polo-like kinase 1. Li Z; Zhang Z; Chen Y; Tang S; Lin T; Huang J; Li B; Jiang C Bioorg Chem; 2019 Apr; 85():534-540. PubMed ID: 30807896 [TBL] [Abstract][Full Text] [Related]
16. Development of a High-Throughput Assay for Inhibitors of the Polo-Box Domain of Polo-Like Kinase 1 Based on Time-Resolved Fluorescence Energy Transfer. Kim TG; Lee JH; Lee MY; Kim KU; Lee JH; Park CH; Lee BH; Oh KS Biol Pharm Bull; 2017; 40(9):1454-1462. PubMed ID: 28867728 [TBL] [Abstract][Full Text] [Related]
17. Identification of novel peptidomimetics targeting the polo-box domain of polo-like kinase 1. Li Z; Zhang Z; Sun H; Xu L; Jiang C Bioorg Chem; 2019 Oct; 91():103148. PubMed ID: 31376784 [TBL] [Abstract][Full Text] [Related]
18. Virtual screening of natural compounds as selective inhibitors of polo-like kinase-1 at C-terminal polo box and N-terminal catalytic domain. Olawale F; Iwaloye O; Elekofehinti OO J Biomol Struct Dyn; 2022; 40(24):13606-13624. PubMed ID: 34669551 [TBL] [Abstract][Full Text] [Related]
19. A case study from the chemistry core of the Pittsburgh Molecular Library Screening Center: the Polo-like kinase polo-box domain (Plk1-PBD). Wipf P; Arnold D; Carter K; Dong S; Johnston PA; Sharlow E; Lazo JS; Huryn D Curr Top Med Chem; 2009; 9(13):1194-205. PubMed ID: 19807663 [TBL] [Abstract][Full Text] [Related]
20. Dynamic and multi-pharmacophore modeling for designing polo-box domain inhibitors. Sakkiah S; Senese S; Yang Q; Lee KW; Torres JZ PLoS One; 2014; 9(7):e101405. PubMed ID: 25036740 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]